Clinical Trials

1,000 enrolled

Breast Neoplasms

NCT05664893 2026-04-15

CALHYS

Phase 1/2 Withdrawn

HER2 Negative Breast Cancer Not Immediately Operated

NCT04920708 2026-04-14

FAIM

57 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05358249 2026-04-14

KontRASt-03

Phase 1/2 Active not recruiting

74 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT06380751 2026-04-14

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT07400523 2026-04-14

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

446 enrolled

Breast Neoplasms

NCT04802759 2026-04-13

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

316 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Available

BreastGastrointestinalThoracic

Breast Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

392 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07164976 2026-04-13

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

86 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07391774 2026-04-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

1,978 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT05467891 2026-04-08

RaPhLRR

200 enrolled

Locoregional Recurrence

NCT06188520 2026-04-08

CYCAD-1

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

46 enrolled

Other solid neoplasm

Solid Tumors

NCT06065748 2026-04-06

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07405801 2026-04-06

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

80 enrolled

Phase 4 Active not recruiting

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07340658 2026-04-02

SIE-3

300 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

255 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT03701334 2026-04-01

NATALEE

5,101 enrolled 5 FDA

Breast Neoplasms

NCT04943497 2026-04-01

PROSPERITY

Completed

2,424 enrolled

Breast Neoplasms

NCT06830720 2026-04-01

CAROLEEN

3,250 enrolled

Breast Neoplasms

NCT06905301 2026-04-01

IMPULSE

240 enrolled

Breast Neoplasms

NCT07054190 2026-03-31

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

60 enrolled

Breast Neoplasms

NCT06726148 2026-03-27

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

280 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07492641 2026-03-25

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

1,056 enrolled

HR+/HER2- Breast Cancer

NCT07487129 2026-03-23

Clinical and P

Phase 4 Completed

206 enrolled

Breast Neoplasms

NCT05843253 2026-03-20

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

120 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT07174336 2026-03-20

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06377852 2026-03-18

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

500 enrolled

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Breast Neoplasms

NCT05697146 2026-03-16

RosaLEE

Active not recruiting

1,019 enrolled

Breast Neoplasms

NCT06930859 2026-03-16

ELEGANCE

2,766 enrolled

Breast Neoplasms

NCT07237256 2026-03-16

NoLEEta

3,902 enrolled

Breast Neoplasms

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

134 enrolled

Dermatologic

Melanoma

NCT04862663 2026-03-12

CAPItello-292

895 enrolled

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT02712723 2026-03-11

FELINE

121 enrolled 9 charts

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT02780128 2026-03-10

NEPENTHE

Phase 1 Terminated

66 enrolled

CNS

Neoplasms, Neuroblastoma

NCT05573555 2026-03-09

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

20 enrolled

Phase EARLY_PHASE1 Active not recruiting

Breast Neoplasms

NCT02933736 2026-03-06

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

48 enrolled

CNS

Glioblastoma, Meningioma

NCT05768139 2026-03-02

PIKALO-1

BreastGynecologicHead & Neck

720 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06760637 2026-03-02

FourLight-3

1,020 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT02645149 2026-02-27

Match Mel

Phase 2 Completed

216 enrolled

Dermatologic

Melanoma

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT03008408 2026-02-11

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

90 enrolled

Gynecologic

Endometrial Neoplasms

NCT06757634 2026-02-05

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

674 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06797531 2026-02-04

NISLEESA

177 enrolled